BRPI1015917A2 - antígenos de rsv recombinantes. - Google Patents
antígenos de rsv recombinantes.Info
- Publication number
- BRPI1015917A2 BRPI1015917A2 BRPI1015917A BRPI1015917A BRPI1015917A2 BR PI1015917 A2 BRPI1015917 A2 BR PI1015917A2 BR PI1015917 A BRPI1015917 A BR PI1015917A BR PI1015917 A BRPI1015917 A BR PI1015917A BR PI1015917 A2 BRPI1015917 A2 BR PI1015917A2
- Authority
- BR
- Brazil
- Prior art keywords
- rsv
- recombinant
- antigen
- respiratory syncytial
- syncytial virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"antígeno de vírus sincicial respiratório recombinante, composição imunogênica, ácido nucleico recombinante, uso do antígeno de rsv, método para produzir um antígeno de rsv recombinante com um padrão de glicosilação alterado e método para aumentar a expressão de um polipeptídeo de proteína de fusão de rsv" esta divulgação fornece antígenos de vírus sincicial respiratório (rsv) recombinantes e métodos para fabricar e usar os mesmos, incluindo composições imunogênicas (por exemplo, vacinas) para o tratamento e/ou prevenção de infecção por rsv.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21996409P | 2009-06-24 | 2009-06-24 | |
US33456810P | 2010-05-13 | 2010-05-13 | |
PCT/EP2010/059008 WO2010149745A1 (en) | 2009-06-24 | 2010-06-24 | Recombinant rsv antigens |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI1015917A2 true BRPI1015917A2 (pt) | 2019-08-27 |
Family
ID=42670494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1015917A BRPI1015917A2 (pt) | 2009-06-24 | 2010-06-24 | antígenos de rsv recombinantes. |
Country Status (29)
Country | Link |
---|---|
US (1) | US9492531B2 (pt) |
EP (1) | EP2445526B1 (pt) |
JP (2) | JP6062245B2 (pt) |
KR (1) | KR101696002B1 (pt) |
CN (1) | CN102481359B (pt) |
AU (2) | AU2010264688A1 (pt) |
BR (1) | BRPI1015917A2 (pt) |
CA (1) | CA2766211A1 (pt) |
CL (1) | CL2011003273A1 (pt) |
CO (1) | CO6480978A2 (pt) |
CR (1) | CR20120025A (pt) |
CY (1) | CY1117673T1 (pt) |
DK (1) | DK2445526T3 (pt) |
DO (1) | DOP2011000389A (pt) |
EA (1) | EA023054B1 (pt) |
ES (1) | ES2583257T3 (pt) |
HR (1) | HRP20160798T1 (pt) |
HU (1) | HUE028085T2 (pt) |
IL (1) | IL217013B (pt) |
MA (1) | MA33449B1 (pt) |
MX (1) | MX2012000035A (pt) |
PE (1) | PE20121541A1 (pt) |
PL (1) | PL2445526T3 (pt) |
PT (1) | PT2445526T (pt) |
SG (1) | SG176829A1 (pt) |
SI (1) | SI2445526T1 (pt) |
UA (1) | UA111141C2 (pt) |
WO (1) | WO2010149745A1 (pt) |
ZA (1) | ZA201109199B (pt) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4108688A1 (en) | 2007-12-24 | 2022-12-28 | ID Biomedical Corporation of Quebec | Recombinant rsv antigens |
US8715692B2 (en) * | 2008-12-09 | 2014-05-06 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
US8889146B2 (en) * | 2009-06-24 | 2014-11-18 | Glaxosmithkline Biologicals, Sa | Vaccine |
SG178026A1 (en) | 2009-07-15 | 2012-03-29 | Novartis Ag | Rsv f protein compositions and methods for making same |
US20140248314A1 (en) * | 2011-05-13 | 2014-09-04 | Novartis Ag | Pre-fusion rsv f antigens |
CN102294027A (zh) * | 2011-07-26 | 2011-12-28 | 昆明理工大学 | 一种呼吸道合胞病毒f2蛋白亚单位疫苗及其制备方法 |
EP2752199A4 (en) | 2011-08-29 | 2015-04-29 | Univ Tokushima | RSV MUCOSA VACCINE |
CA2850296C (en) | 2011-10-03 | 2021-01-12 | Moreinx Ab | Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds |
CN102743750B (zh) * | 2012-07-09 | 2013-11-20 | 江苏省农业科学院 | 一种复方免疫增强剂、禽用疫苗及其制备方法 |
KR102264852B1 (ko) | 2012-08-01 | 2021-06-14 | 버베리안 노딕 에이/에스 | 재조합 변형된 백시니아 바이러스 앙카라(ankara) (mva) 호흡기 신시티알 바이러스(rsv) 백신 |
JP2015525794A (ja) * | 2012-08-06 | 2015-09-07 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 乳児においてrsv及び百日咳菌に対する免疫応答を惹起するための方法 |
US20140037680A1 (en) * | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
MX2015013065A (es) * | 2013-03-13 | 2016-06-06 | Us Health | Proteinas f de rsv de prefusion y su uso. |
US9738689B2 (en) | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
US9060975B2 (en) | 2013-03-14 | 2015-06-23 | Mucosis Bv | Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions |
CN103204943B (zh) * | 2013-03-20 | 2014-07-23 | 中国科学院武汉病毒研究所 | 呼吸道合胞病毒F蛋白与Fc的融合蛋白及其用途 |
BR112015025392A2 (pt) * | 2013-04-08 | 2017-10-10 | Medimmune Llc | composição de vacina e método de utilização |
EA035522B1 (ru) | 2013-04-25 | 2020-06-29 | Янссен Вэксинс Энд Превеншн Б.В. | Стабильные растворимые f-полипептиды rsv в конформации "до слияния" |
CA2914792C (en) | 2013-06-17 | 2024-02-27 | Crucell Holland B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
CA2919773A1 (en) * | 2013-08-05 | 2015-02-12 | Glaxosmithkline Biologicals S.A. | Combination immunogenic compositions |
US9322037B2 (en) * | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
MX2016016533A (es) * | 2014-06-13 | 2017-05-01 | Glaxosmithkline Biologicals Sa | Combinaciones inmunogenas. |
US10457708B2 (en) | 2015-07-07 | 2019-10-29 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
IL288541B (en) | 2015-07-07 | 2022-08-01 | Janssen Vaccines Prevention B V | vaccine against rsv |
SG11201804148TA (en) | 2015-12-23 | 2018-07-30 | Pfizer | Rsv f protein mutants |
JP7233928B2 (ja) | 2016-04-05 | 2023-03-07 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Rsvに対するワクチン |
SG11201807913XA (en) | 2016-04-05 | 2018-10-30 | Janssen Vaccines & Prevention Bv | Stabilized soluble pre-fusion rsv f proteins |
WO2017207477A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
IL264119B2 (en) | 2016-05-30 | 2023-04-01 | Janssen Vaccines Prevention B V | f proteins of rsv are stabilized before fusion |
CN115442571A (zh) * | 2016-09-23 | 2022-12-06 | 伊姆西Ip控股有限责任公司 | 用于视频监控系统的故障恢复方法和装置 |
TWI683826B (zh) * | 2016-11-22 | 2020-02-01 | 國立臺灣大學 | 重組rsv抗原 |
GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
EP3624845A1 (en) | 2017-05-15 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
JP2020519666A (ja) | 2017-05-15 | 2020-07-02 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | 安定性のウイルス含有組成物 |
AU2018267971A1 (en) | 2017-05-17 | 2019-11-07 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
IE87413B1 (en) | 2017-05-30 | 2023-07-19 | Glaxosmithkline Biologicals Sa | Novel methods for manufacturing an adjuvant |
CN110891592A (zh) | 2017-06-14 | 2020-03-17 | 维罗米蒂克斯股份公司 | 用于保护免受呼吸道合胞病毒的环状肽 |
US11229695B2 (en) | 2017-09-15 | 2022-01-25 | Janssen Vaccines & Prevention B.V. | Method for the safe induction of immunity against RSV |
CA3083078A1 (en) | 2017-12-01 | 2019-06-06 | Glaxosmithkline Biologicals Sa | Saponin purification |
BR112021000965A2 (pt) | 2018-08-07 | 2021-04-27 | Glaxosmithkline Biologicals S.A. | processos e vacinas |
CR20210306A (es) | 2018-11-13 | 2021-07-22 | Janssen Vaccines & Prevention Bv | Proteínas f de prefusión del vrs estabilizadas |
JP2022514411A (ja) | 2018-12-20 | 2022-02-10 | ヴァイロメティックス アーゲー | リポペプチドビルディングブロックおよび合成ウイルス様粒子 |
CN113543803A (zh) * | 2019-02-28 | 2021-10-22 | Km生物医药股份公司 | Rsv f/g嵌合疫苗 |
CA3142300A1 (en) | 2019-06-05 | 2020-12-10 | Glaxosmithkline Biologicals Sa | Saponin purification |
JP2022060169A (ja) | 2020-10-02 | 2022-04-14 | ファイザー・インク | Rsv fタンパク質生産のための細胞培養工程 |
CN114685627A (zh) * | 2020-12-28 | 2022-07-01 | 广州更新生物医药科技有限公司 | 一种预防呼吸道合胞病毒的rAAV载体疫苗 |
EP4294436A1 (en) | 2021-02-19 | 2023-12-27 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv fb fantigens |
EP4169513A1 (en) | 2021-10-19 | 2023-04-26 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising sting agonists |
CN115772230A (zh) * | 2022-07-18 | 2023-03-10 | 青岛硕景生物科技有限公司 | 一种rsv重组抗原、其制备方法及应用 |
WO2024069420A2 (en) | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Immunogenic compositions comprising an rsv f protein trimer |
WO2024089634A1 (en) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Immunogenic compositions against influenza and rsv |
WO2024089633A1 (en) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Rna molecules encoding rsv-f and vaccines containing them |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
US4707543A (en) | 1985-09-17 | 1987-11-17 | The United States Of America As Represented By The Secretary Of The Army | Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines |
US5149650A (en) | 1986-01-14 | 1992-09-22 | University Of North Carolina At Chapel Hill | Vaccines for human respiratory virus |
US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US5726292A (en) | 1987-06-23 | 1998-03-10 | Lowell; George H. | Immuno-potentiating systems for preparation of immunogenic materials |
ATE85622T1 (de) | 1987-12-23 | 1993-02-15 | Upjohn Co | Chimarenglykoproteine, enthaltend immunogene segmente des humanen respiratorischen synzytialvirus. |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
JP3755890B2 (ja) | 1992-06-25 | 2006-03-15 | スミスクライン・ビーチャム・バイオロジカルス(ソシエテ・アノニム) | アジュバント含有ワクチン組成物 |
AU5955294A (en) | 1993-01-08 | 1994-08-15 | Upjohn Company, The | Process for the purification and refolding of human respiratory syncytial virus fg glycoprotein |
EP0812593B8 (en) | 1993-03-23 | 2010-11-10 | SmithKline Beecham Biologicals S.A. | Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a |
US5961970A (en) | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
RU2154068C2 (ru) | 1993-11-17 | 2000-08-10 | Лаборатуар Ом С.А. | Глюкозаминовые дисахариды, способ их получения, фармацевтическая композиция |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
FR2718452B1 (fr) | 1994-04-06 | 1996-06-28 | Pf Medicament | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. |
DK0772619T4 (da) | 1994-07-15 | 2011-02-21 | Univ Iowa Res Found | Immunmodulatoriske oligonukleotider |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US5666153A (en) | 1995-10-03 | 1997-09-09 | Virtual Shopping, Inc. | Retractable teleconferencing apparatus |
US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6060308A (en) * | 1997-09-04 | 2000-05-09 | Connaught Laboratories Limited | RNA respiratory syncytial virus vaccines |
EP1015595B1 (en) | 1997-09-19 | 2005-01-26 | Wyeth Holdings Corporation | Peptides derived from the attachment (g) protein of respiratory syncytial virus |
GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
HUP0102332A3 (en) | 1998-06-08 | 2002-11-28 | Sca Emballage France | Fast flattening packaging |
PL195764B1 (pl) | 1998-06-30 | 2007-10-31 | Om Pharma | Pseudodipeptydy N-acylowe, sposoby wytwarzania pseudodipeptydów N-acylowych i kompozycje farmaceutyczne |
TR200101055T2 (tr) | 1998-10-16 | 2001-09-21 | Smithkline Beecham Biologicals S.A. | Adjuvan sistemler ve aşılar |
US20040006242A1 (en) | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
AU1581400A (en) | 1999-12-22 | 2001-07-03 | Om Pharma | Acyl pseudopeptides bearing a functionalised auxiliary spacer |
AU2002223275A1 (en) * | 2000-11-22 | 2002-06-03 | Biota Scientific Management Pty Ltd | A method of expression and agents identified thereby |
ES2330201T3 (es) | 2001-01-26 | 2009-12-07 | Selexis S.A. | Regiones de union a la matriz y metodos para el uso de las mismas. |
AU2002245636B2 (en) | 2001-03-09 | 2004-10-14 | Id Biomedical Corporation Of Quebec | A novel proteosome-liposaccharide vaccine adjuvant |
KR100892614B1 (ko) | 2001-04-17 | 2009-04-09 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 신규 아데닌 유도체 |
US20040014779A1 (en) | 2001-11-16 | 2004-01-22 | 3M Innovative Properties Company | Methods and compositions related to IRM compounds and toll-like recptor pathways |
JP2006517974A (ja) | 2003-02-13 | 2006-08-03 | スリーエム イノベイティブ プロパティズ カンパニー | Irm化合物およびトル様受容体8に関する方法および組成物 |
US7368537B2 (en) | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
AU2004284220B2 (en) | 2003-10-24 | 2010-10-14 | Selexis S.A. | High efficiency gene transfer and expression in mammalian cells by a multiple transfection procedure of matrix attachment region sequences |
FR2873378A1 (fr) | 2004-07-23 | 2006-01-27 | Pierre Fabre Medicament Sa | Complexes immunogenes, leur procede de preparation et leur utilisation dans des compositions pharmaceutiques |
GB0422439D0 (en) | 2004-10-08 | 2004-11-10 | European Molecular Biology Lab Embl | Inhibitors of infection |
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
WO2008061243A2 (en) * | 2006-11-16 | 2008-05-22 | Novavax, Inc. | Respiratory syncytial virus-virus like particle (vlps) |
CA2684578A1 (en) | 2007-03-21 | 2008-09-25 | Id Biomedical Corporation Of Quebec | Chimeric antigens |
US20100261155A1 (en) | 2007-06-06 | 2010-10-14 | Nationwide Children's Hospital, Inc. | Methods and compositions relating to viral fusion proteins |
EP4108688A1 (en) | 2007-12-24 | 2022-12-28 | ID Biomedical Corporation of Quebec | Recombinant rsv antigens |
KR20110045008A (ko) | 2008-07-18 | 2011-05-03 | 아이디 바이오메디컬 코포레이션 오브 퀘벡 | 키메라 호흡기 세포융합 바이러스 폴리펩티드 항원 |
US8889146B2 (en) | 2009-06-24 | 2014-11-18 | Glaxosmithkline Biologicals, Sa | Vaccine |
-
2010
- 2010-06-24 CN CN201080037770.3A patent/CN102481359B/zh not_active Expired - Fee Related
- 2010-06-24 BR BRPI1015917A patent/BRPI1015917A2/pt not_active Application Discontinuation
- 2010-06-24 AU AU2010264688A patent/AU2010264688A1/en not_active Abandoned
- 2010-06-24 WO PCT/EP2010/059008 patent/WO2010149745A1/en active Application Filing
- 2010-06-24 PL PL10724879T patent/PL2445526T3/pl unknown
- 2010-06-24 CA CA2766211A patent/CA2766211A1/en not_active Abandoned
- 2010-06-24 HU HUE10724879A patent/HUE028085T2/en unknown
- 2010-06-24 DK DK10724879.1T patent/DK2445526T3/en active
- 2010-06-24 UA UAA201200714A patent/UA111141C2/uk unknown
- 2010-06-24 KR KR1020127001782A patent/KR101696002B1/ko active IP Right Grant
- 2010-06-24 EP EP10724879.1A patent/EP2445526B1/en active Active
- 2010-06-24 MA MA34557A patent/MA33449B1/fr unknown
- 2010-06-24 SG SG2011092319A patent/SG176829A1/en unknown
- 2010-06-24 JP JP2012516746A patent/JP6062245B2/ja not_active Expired - Fee Related
- 2010-06-24 EA EA201270063A patent/EA023054B1/ru not_active IP Right Cessation
- 2010-06-24 MX MX2012000035A patent/MX2012000035A/es active IP Right Grant
- 2010-06-24 US US13/378,391 patent/US9492531B2/en not_active Expired - Fee Related
- 2010-06-24 PE PE2011002168A patent/PE20121541A1/es not_active Application Discontinuation
- 2010-06-24 PT PT107248791T patent/PT2445526T/pt unknown
- 2010-06-24 SI SI201031234A patent/SI2445526T1/sl unknown
- 2010-06-24 ES ES10724879.1T patent/ES2583257T3/es active Active
-
2011
- 2011-12-14 ZA ZA2011/09199A patent/ZA201109199B/en unknown
- 2011-12-14 DO DO2011000389A patent/DOP2011000389A/es unknown
- 2011-12-15 IL IL217013A patent/IL217013B/en not_active IP Right Cessation
- 2011-12-22 CL CL2011003273A patent/CL2011003273A1/es unknown
- 2011-12-29 CO CO11181053A patent/CO6480978A2/es unknown
-
2012
- 2012-01-16 CR CR20120025A patent/CR20120025A/es unknown
-
2014
- 2014-07-03 AU AU2014203636A patent/AU2014203636C1/en not_active Ceased
-
2016
- 2016-01-14 JP JP2016005403A patent/JP2016128457A/ja active Pending
- 2016-06-21 CY CY20161100557T patent/CY1117673T1/el unknown
- 2016-07-06 HR HRP20160798TT patent/HRP20160798T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI1015917A2 (pt) | antígenos de rsv recombinantes. | |
CY1123152T1 (el) | Τροποποιημενες πρωτεϊνες rsv f και μεθοδοι χρησης τους | |
EA201070794A1 (ru) | Рекомбинантные антигены rsv | |
MX2019006349A (es) | Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas. | |
CL2012000119A1 (es) | Polipeptido f de virus respiratorio sincicial recombinante, composicion inmunogenica que lo comprende, uso para la preparacion de un medicamento para la profilaxis contra dicho virus. | |
DK1881845T3 (da) | Nipah-virusvacciner | |
PE20190420A1 (es) | Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas | |
WO2007011904A3 (en) | Recombinant flu vaccines | |
NZ627888A (en) | Materials and methods for respiratory disease control in canines | |
MX2021010519A (es) | Proteinas f de rsv de prefusion y su uso. | |
GEP20217260B (en) | Antibody neutralizing human respiratory syncytial virus | |
WO2007095318A3 (en) | Influenza antigens, vaccine compositions, and related methods | |
AR046677A1 (es) | Formas solidas de anticuerpos anti-egfr | |
WO2007064742A3 (en) | Identification of protective antigenic determinants of porcine reproductive and respiratory syndrome virus (prrsv) and uses thereof | |
MX2012000036A (es) | Vacuna. | |
WO2010039224A3 (en) | Respiratory syncytial virus (rsv) sequences for protein expression and vaccines | |
PE20140986A1 (es) | Proteinas de fusion y vacunas de combinacion que comprenden proteina e y pilina a de haemophilus influenzae | |
BRPI0707779B8 (pt) | antígeno isolado, composição de vacina e método para produção de uma proteína antígeno | |
GEP201706766B (en) | Methods and compositions for vaccinating against staphylococcus aureus | |
WO2008118487A3 (en) | Compositions and methods for incresing immunogenicity of glycoprotein vaccines | |
WO2008124176A3 (en) | Soluble and membrane-anchored forms of lassa virus subunit proteins | |
WO2009005917A3 (en) | Methods of treating measles infectious disease in mammals | |
WO2008027414A3 (en) | Novel p. falciparum vaccine proteins and coding sequences | |
TR201905336T4 (tr) | Rekombinant rsv antijenleri. | |
EA202091829A1 (ru) | Конструкты антител на основе нуклеиновой кислоты для использования против респираторного синцитиального вируса |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |